Experimental oral therapy PrimeC shows safety and signals of clinical benefit in ALS
In a phase 2b clinical trial, an investigational oral therapy called PrimeC was found to be safe and well tolerated in people living with amyotrophic lateral sclerosis (ALS), with exploratory findings suggesting target engagement ...
5 hours ago
0
0









